https://orcid.org/0000-0002-2620-0591
Figures
Abstract
Introduction
Hemodialysis patients rely on stable vascular access to perform effective hemodialysis and reach good dialysis quality. However, an obstructed or under-matured arteriovenous fistula (AVF) may increase infection rate and mortality in hemodialysis patients. Far infrared (FIR) therapy might help to promote AVF maturation and reduce obstruction rate. Therefore, this meta-analysis was conducted to evaluate the effect of FIR therapy on AVF obstruction rate and maturation.
Material and method
PubMed, Embase, the Cochrane Library, and other databases which provide publications in randomized controlled trials (RCTs) of FIR to improve AVF in patients with CKD (Chronic Kidney Disease) or HD (hemodialysis) were used to collect articles which published before February 2023. Two authors selected relevant articles independently based on pre-defined inclusion and exclusion criteria, and assessed the quality of the articles by using the Cochrane Handbook before performing a meta-analysis in Review Manager (RevMan) 5.4 software.
Results
Four RCTs with 475 patients were included. The results of the meta-analysis showed that the FIR therapy groups had better physiological maturation at 3 months (RR = 1.22; 95% CI = 1.07 to 1.39; p = .002) and clinical maturation at 12 months (RR = 1.35; 95% CI = 1.14 to 1.60; p < .001) than the control groups without FIR therapy. The obstruction rates within 12 months were much lower in the FIR therapy groups than in the control groups (RR = 0.24; 95% CI = 0.08 to 0.68; p = .007), also, there was no statistical heterogeneity.
Citation: Wu C-F, Yeh T-P, Lin T-C, Huang P-H, Huang P-J (2024) Effects of far infrared therapy in hemodialysis arterio-venous fistula maturation: A meta-analysis. PLoS ONE 19(8): e0307586. https://doi.org/10.1371/journal.pone.0307586
Editor: Ahmet Murt, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, TÜRKIYE
Received: July 27, 2023; Accepted: July 8, 2024; Published: August 28, 2024
Copyright: © 2024 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript.
Funding: This research was funded by China Medical University, CMU108-TC-01, Tzu-Pei Yeh was the principal investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
According to the United States Renal Data System (USRDS) 2022 annual report, the number of people receiving hemodialysis (HD) in the United States almost doubled from 2000 to 2020, reached 480,516. In addition, the total number of people had new registrations with End-Stage Renal Disease (ESRD) in 2020 was 130,522; 109,107 patients of this population (83.9%) chose HD as renal replacement therapy [1]. To obtain the optimal HD treatment results in the clinic, patients need to rely on full-functional and stable vascular access for hemodialysis. Studies have shown that if a patient starts HD with a catheter at the beginning of dialysis, the mortality rate within 18 months is more than twice than those who with an arteriovenous fistula (AVF) at the beginning [1]. Therefore, the first-choice of access for HD is AVF, because it has fewer complications, better overall patency, and lower mortality than other types of vascular access [1–4]. However, it takes several months for a new AVF to be mature for use and the cumulative incidence of primary unassisted patency is only 59.1% [1, 5]. Approximately 50% patients had poor fistula maturity and needed endovascular or surgical procedures to promote AVF maturation [6, 7]. Despite the optimization in the maintenance of the AVF, obstruction still occurs [7, 8] or its maturation is insufficient; this may force patients to depend on the central venous catheter for longer time and increase the risks of catheter infection [6, 7]. This may make a significant impact on patients’ lives and require huge medical costs and resources.
Far infrared (FIR) is an invisible electromagnetic wave. FIR therapy (FIR) uses low-power electromagnetic waves emitted from far infrared to improve human physiological functions (wavelengths of 3–100 μm). Previous studies showed that FIR therapy could effectively suppress inflammation; and it has been widely used in the clinical treatment of various diseases in recent years, such as post-catheterization patients in FIR saunas [9, 10]. The use of FIR therapy to improve vascular access flow and patency is based on the influences of local vasodilation which not only induced by thermal effects, but more importantly by non-thermal effects to improve endothelial function [11–13]. The treatment effects above may due to the ability of FIR could effectively activate the heme oxygenase-1 gene (HO-1), as HO-1 is effective in reducing inflammation. HO-1 also work on inhibiting vascular smooth muscle cell proliferation and stimulates endothelial cell regeneration at the site of endothelial injury; thereby the occurrence of vascular stenosis could be reduced [14, 15].
FIR therapy has been used in recent decade to promote AVF maturation with the goal of increasing vascular access flow and patency. In 2014, Bashar et al. [16] conducted a meta-analysis of the effects of FIR therapy on increasing the patency of primary and secondary AVF. In 2017, Wan et al. [12] also conducted a meta-analysis on the effect of FIR treatment on AVF patency, but the results of this review were too heterogeneous and most of the studies which met the inclusion criteria were not available in full text; consequently the reliability of the results was reduced. Therefore, our research team conducted a systematic review (SR) and meta-analysis (MA) to evaluate the impact of FIR therapy on AVF maturity and patency.
Material and method
This systematic review and meta-analysis was conducted following the PRISMA guidelines for Systematic Reviews and Meta-Analyses [17].
Search strategies
PubMed, EMBASE, Cochrane Library, Web of Science, and other databases were searched to obtain RCTs which may answer the question until February 2023. The following keywords were used and searched by using Boolean algebra: "chronic kidney disease or dialysis, hemodialysis, end-stage renal disease, renal failure, fistula, arterial fistula, graft, far-infrared therapy, far-infrared. The bibliographies of included studies were also been searched to find out more related studies.
The inclusion criteria were
- Study type: Studies designed with RCTs
- Participant Type: patients diagnosed with CKD or ESRD, and receiving regular HD treatment with AVF.
- Intervention type: FIR therapy versus non- FIR therapy.
- Outcome measurement types: maturation, patency, access flow, inside diameter, occlusion rates of AVF.
- No restrictions on publication types or languages.
The exclusion criteria were
- Non-RCTs and case reports were excluded.
- Study on patients cross-treated with peritoneal dialysis.
- No full texts available such as conference paper which without research details.
Data extraction and quality assessment
Two evaluators (C.F.W. and P.J.H) extracted data from the included studies and assessed the quality studies by using the Cochrane Risk of Bias tool independently. If there was any disagreement in terms of the literature inclusion, the two evaluators would discuss with the third author (T.P.Y) to reach the consensus.
The evaluation items of the quality assessment including: 1) Selection bias: Are the randomization or blinding processes and methods described clearly? 2) Detection bias: Is the preventions of knowledge related to intervention allocations appropriately? 3) Lost data bias: Has missing data been addressed? 4) Reporting bias and 5) other biases [18].
Statistical analysis
Statistical analysis of comparable data was performed by using Review Manager 5.4 software (Table 1). The result of continuous variable were analysis in standardized mean differences (SMD). Dichotomous variable results were revealed in risk ratios (RR) and 95% confidence intervals (CI). χ2 and I2 tests (I2 > 50% was considered significant heterogeneity) were used to assess data heterogeneity. When heterogeneity was low, fixed-effects models were applied to conduct the meta-analysis. Otherwise, a random effects model was used to reduce the effect of statistical heterogeneity [19]. The overall effects were examined by z-test, and p-values < 0.05 were considered as statistically significant. Besides, if there is any parameter with high heterogeneity, we use power analysis through R language (version 4.3.2 for Windows, 79 megabytes, 64 bit) to evaluate the power of evidence.
Results
Study selection
In Fig 1, 387 studies were identified after searching from multiple electronic databases, studies which irrelevant and duplicative were excluded. The full texts of the remaining 37 articles were further reviewed, and after filtering by inclusion and exclusion criteria, four eligible studies were included in the meta-analysis [7, 20–22]. During the literatures screening process, although both the papers of Lai et al. 2013 [23] and Lin et al. 2013 [15] used FIR therapy and targeted in patients with AVF; however, direct effects (such as patency and occlusion) of FIR on AVF were not indicated in Lin 2013 [15], and the participants in Lai et al. 2013 [23] included post AVF Percutaneous Transluminal Angioplasty (PTA) which may impact the statistical results hugely. Therefore, these two related RCTs were excluded for meta-analysis.
Characteristics of included studies
In Table 2, the summary of the four literatures including: countries, study period, study designs, interventions, and sample sizes are represented.
Table 3 presents baseline characteristics of included studies, such as patient source, mean age, treatment, HD machines, protocol settings and frequency of FIR therapy.
The inclusion and exclusion criteria of the participant selection, the definitions of AVF malfunction in each study are presented in Table 4. The main model WS TY101 (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to provide the FIR therapy, which may produce wavelengths in the range between 3 to 25 μm (with peaks of 5 to 8 μm). The top radiator was placed at a height of 25–30 cm above the AVF surface and the therapy time is set for 40 minutes and 2–3 times per week.
Risk of bias in included studies
Overall, only one trail did not reveal the randomization method, and three trials clearly described the randomization and allocation methods [7, 20–22]. Although all participants were not blinded, the assessors in four trials were blinded [7, 20–22]. Three studies reported participant dropouts [7, 20, 21]. All studies presented outcomes measurement methods and adverse events (Fig 2).
Effects of FIR on AVF maturation and unassisted patency
In terms of fistula maturity, both physiological maturity at 3 months (RR = 1.22; 95%CI = 1.07 to 1.39; p = .002; Fig 3) and clinical maturity at 12 months (RR = 1.35; 95%CI = 1.14 to 1.60; p < .001; Fig 4) shows significant differences between the two groups, the FIR therapy groups were better than the control groups. The FIR groups also showed higher and significant differences in unassisted patency (RR = 1.27; 95%CI = 1.09 to 1.47; p = .002; I2 = 0%; Fig 5) at 12 months without any intervention. There was no evidence of statistical heterogeneity (df = 1(p = .57); I2 = 0%; Fig 3; df = 1(p = .90); I2 = 0%; Fig 4; df = 1(p = .81); I2 = 0%; Fig 5). This suggests that FIR therapy is benefit in increasing maturation and patency of the AVF.
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.5 Physiologic maturation of AVF at 3mo.
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.6 Clinical maturation of AVF within 12mo.
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.4 Unassisted patency of AVF at 12 mo.
Effects of FIR on access flow at different stages
In terms of the effects of FIR on Qa (access flow), there was no difference between the two groups when measured the Qa0 on baseline when AVF was established (RR = -0.01; 95%CI = -0.28 to 0.25; p = .91; Fig 6). All studies had Qa1 in the 1st-month and Qa3 in the 6th-months, Qa2 had only done in the 3rd-months in Lin et al. [20] and Lin et al. [21], and Qa4 had been completed in the 12th-months in Chen et al. [7] and Lin et al. [20]. In FIR therapy groups, all studies showed the increasing of vascular access flow (RR = 0.43; 95%CI = 0.09 to 0.76; p = .01; 1-month; Fig 7; RR = 0.49; 95%CI = 0.26 to 0.72; p < .001; 6-months; Fig 8). There was no statistical difference in Qa2 at 3rd-months (RR = 0.26; 95%CI = -0.38 to 0.90; p = .42; Fig 9) and 12th-months (RR = 1.74; 95%CI = -0.37 to 3.84; p = .11, Fig 10) after AVF establishment. The four studies included in the meta-analysis showed considerable heterogeneity at 1st-month (df = 3 (p = .02); I2 = 69%; Fig 7), 3-months (df = 1 (p = .01); I2 = 85%; Fig 9) and 12th -months (df = 1 (p < .01); I2 = 98%; Fig 10) and a low heterogeneity at 6th-months (df = 3 (p = .21); I2 = 34%; Fig 8) in each sub-group. Therefore, the effects of FIR on vascular access flow needs to be further discussed and investigated. Besides, high heterogeneity had been detected in Qa1 (I2 = 69%), Qa2 (I2 = 85%), and Qa4 (I2 = 98%). The result of power analysis showed statistical power on each parameter as Qa1 (Power = 89.42%), Qa2 (Power = 30.44%), and Qa4 (Power = 100%).
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.7 Assessment of Qa0 (mL/min).
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.8 Assessment of Qa1 (mL/min).
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.10 Assessment of Qa3 (mL/min).
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.9 Assessment of Qa2 (mL/min).
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.11 Assessment of Qa4 (mL/min).
Effect of FIR on malfunction within 12-months
Three studies analyzed AVF malfunction status by using a random effects model (n = 368). The meta-analysis results revealed a lower failure rate of AVF in the FIR intervention groups (RR = 0.42; 95% CI = 0.28 to 0.65; p < .001; Fig 11) and no heterogeneity was found (df = 2(p = .970); I2 = 0%).
1 Far infra-Red phototherapy for AVF malfunction, outcome: 1.1 AVF malfunction.
Effect of FIR on intervention and occlusion rate within 12-months
In the FIR group, further interventions such as PTA or thrombectomy to maintain AVF function was lower (RR = 0.49; 95% CI = 0.025 to 0.96; p = .04; Fig 12) and the obstruction rates within 12-months was much lower in the FIR groups (RR = 0.24; 95% CI = 0.08 to 0.68; p = .007, Fig 13) and no statistical heterogeneity (df = 1 (p = .70); I2 = 0%; Fig 12; df = 1 (p = .59); I2 = 0%; Fig 13). This suggested advantages of FIR therapy in reducing AVF occlusion incidences.
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.2 Intervention for AVF.
1 Far infra-Red phototherapy for AVF malformation, outcome: 1.3 AVF occlusion within 12mo.
Discussion
This meta-analysis integrated data from four RCTs, there were no significant differences in the participants’ demographic characteristics. The meta-analysis results supported that FIR therapy improves AVF patency, reduces obstructions, and increases fistula maturity; which is consistent with the research findings of Bashar et al. 2014 [16] and Wan et al. 2017 [12].
In the effects of FIR on access flow analysis, all studies showed that the access flow in the FIR group was better than the control group and reached a statistically significant difference. However, in this meta-analysis, the results showed only in the control group at Qa1 and Qa3 revealed statistically significant effects; while no significant differences were found at Qa2 and Qa4 (Table 1). These results were different from the research of Wan et al. [12] are in 2017, and this may be related to the small number of articles included the Qa2 and Qa4 for analyses. In addition, the study of Lin et al. [20] in 2007 recruited the patients who had already undergone HD with AVF and not with newly established AVF. Therefore, the effects of FIR on access flow need to be further investigated.
The fistula maturation rates at the 12th month after AVF established in the CKD patients was 58%, and 47.5% patients with newly established AVF required further interventions [5]. This has echoed the percentage of maturation at the 12th month after AVF establishment in the control group in this study (60%-62.7%) [7, 21]. The maturation rate of newly established AVF in FIR therapy groups at 12th- month was 82%-84% in this meta-analysis, which was similar to the Braun and Khayat’s (2021) study. This result may indicate that FIR could improve the maturation rate of new AVF.
Previous study has indicated that the 12th-month unassisted patency after AVF established was 51–72% [4]; but in this meta-analysis, patients with FIR had a patency of 84%-87% with no intervention [7, 21]. The 12th-month unassisted patency in FIR therapy groups in this meta-analysis was similar to the AVF patency (87%) which requiring endovascular or surgical procedures [5]. The cost of performing an endovascular or surgical procedure ranges from $2,000-$4,000 [24], a far-infrared machine (WS TY101 model, for example) costs only about $1,500. Therefore, improving AVF patency and increasing fistula maturity through FIR treatment might significantly reduce the medical costs, which is a ‘win-win’ situation for both patients and medical care units.
The effects of FIR therapy on AVF maturation may result from: (1) inhibition of intimal hyperplasia; (2) reduction of oxidative stress; (3) inhibition of inflammation; and (4) improvement of endothelial function. Studies had demonstrated that FIR may reduce asymmetric dimethylarginine (ADMA), as a result the inflammation and endothelial hyperplasia could be reduced; consequently, the AVF maturation and patency could be enhanced [7, 10, 14, 15, 25, 26]. The effect of FIR treatment on access flow may due to the thermal effects, which would induce vasodilatation and increase access flow; skin surface temperature may only raise to 38–39°C which may avoid burns caused by hot compress [12, 13].
Among the included literature, 2013 Lin et al. [21] and 2020 An et al. [22] both mentioned the effect of FIR on AVF diameter, but since 2020 An [22] included AVF with radio-cephalic fistulas(RCF) and brachio-cephalic fistula (BCF), but 2013 Lin [21] included only RCF, this paper did not compare the effect of FIR on AVF diameter and could not confirm whether FIR Therefore, this paper does not compare the effect of FIR on AVF diameter, and cannot confirm whether FIR has an effect on AVF diameter. The effect of FIR on cardiac output, blood pressure, and total peripheral resistance was only mentioned in the study by 2007 Lin et al. [20], so no analysis of the relevant data was conducted.
There are some study limitations in this meta-analysis. Only four studies were included, which represented a slightly insufficient sample size. Among the four selected studies, three studies had 12 months intervention time, but one study only had a 4-week intervention time; which was inconsistent in intervention duration. Only the AVF of RCF was compared, so that the effect of FIR on BCF could not be investigated. Heterogeneity was persistent in the access flow analysis, although subgroups were used for analysis and random effects model was applied; the heterogeneity may still affect the statistical results. The longest FIR irradiation lasted about 12 months, how the FIR affects primary AVF patency and obstruction rates in more than 12 months remains unknown. Another irradiation duration issue is that whether only 3 months or 6 months intervention could achieve the effect of increasing AVF maturation and reducing subsequent AVF obstruction rates or not? Among the four studies, three were conducted in Taiwan and one is in India, which may have some limitations when the meta-analysis results would like to extrapolate to other populations like European and American countries.
Conclusion
In summary, FIR therapy could effectively improve access flow whether the AVF is new or not; and for new AVFs, FIR therapy can increase AVF maturation and reduce obstruction. Therefore, FIR therapy is a non-invasive treatment modality to improve AVF maturation and patency. FIR therapy is convenient for patients’ use. FIR therapy is also recommended for patients who have DM nephropathy with poor vascular conditions, because it can be used prophylactically to increase the success rate of fistula establishment and reduce the harm caused by poor AVF maturation or obstruction.
Acknowledgments
The authors would like to thank all their colleagues and students who contributed to this study. Special thanks to Chia-Lung Shih for his great efforts in suggestion of statistical analysis.
References
- 1.
United States Renal Data System (USRDS), 2022 Annual Data Report; 2023 March. Available from: https://usrds-adr.niddk.nih.gov/2022
- 2.
hwar HN, Anjum F. Hemodialysis. 2023 Jan 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.
- 3. Hansen EK, Lindhard K, Hansen D. Acute hemodynamic changes during far infrared treatment of the arteriovenous fistula in hemodialysis patients. J Vasc Access. 2021 Oct 29:11297298211052864. Epub ahead of print. pmid:34715757.
- 4. Pisoni RL, Zepel L, Zhao J, Burke S, Lok CE, Woodside KJ, et al. International Comparisons of Native Arteriovenous Fistula Patency and Time to Becoming Catheter-Free: Findings From the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2021 Feb;77(2):245–254. Epub 2020 Sep 21. pmid:32971192.
- 5. Braun MM, Khayat M. Kidney Disease: End-Stage Renal Disease. FP Essent. 2021 Oct;509:26–32. pmid:34643362.
- 6. Huber TS, Berceli SA, Scali ST, Neal D, Anderson EM, Allon M, et al. Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates. JAMA Surg. 2021 Dec 1;156(12):1111–1118. Erratum in: Surg JAMA. 2022 Aug 1;157(8):744. pmid:34550312; PMCID: PMC8459303.
- 7. Chen CF, Lee CY, Chen FA, Yang CY, Chen TH, Ou SM, et al. Far-Infrared Therapy Improves Arteriovenous Fistula Patency and Decreases Plasma Asymmetric Dimethylarginine in Patients with Advanced Diabetic Kidney Disease: A Prospective Randomized Controlled Trial. J Clin Med. 2022 Jul 18;11(14):4168. pmid:35887935; PMCID: PMC9325296.
- 8. Chen CF, Yang WC, Lin CC. An update of the effect of far infrared therapy on arteriovenous access in end-stage renal disease patients. J Vasc Access. 2016 Jul 12;17(4):293–8. Epub 2016 Jun 1. pmid:27312759.
- 9. Beever R. Far-infrared saunas for treatment of cardiovascular risk factors: summary of published evidence. Can Fam Physician. 2009 Jul;55(7):691–6. pmid:19602651; PMCID: PMC2718593.
- 10. Lin YW, Tsai CS, Huang CY, Tsai YT, Shih CM, Lin SJ, et al. Far-Infrared Therapy Decreases Orthotopic Allograft Transplantation Vasculopathy. Biomedicines. 2022 May 7;10(5):1089. pmid:35625826; PMCID: PMC9139124.
- 11. Chen CF, Lee CY, Chen FA, Yang CY, Chen TH, Ou SM, et al. Far-Infrared Therapy Improves Arteriovenous Fistula Patency and Decreases Plasma Asymmetric Dimethylarginine in Patients with Advanced Diabetic Kidney Disease: A Prospective Randomized Controlled Trial. J Clin Med. 2022 Jul 18;11(14):4168. pmid:35887935; PMCID: PMC9325296.
- 12. Wan Q, Yang S, Li L, Chu F. Effects of far infrared therapy on arteriovenous fistulas in hemodialysis patients: a meta-analysis. Ren Fail. 2017 Nov;39(1):613–622. pmid:28805538; PMCID: PMC6446143.
- 13. Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013 Aug;62(2):304–11. Epub 2013 Mar 6. pmid:23474008.
- 14. Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, et al. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):739–45. Epub 2008 Jan 17. pmid:18202320; PMCID: PMC2748062.
- 15. Lin CC, Chung MY, Yang WC, Lin SJ, Lee PC. Length polymorphisms of heme oxygenase-1 determine the effect of far-infrared therapy on the function of arteriovenous fistula in hemodialysis patients: a novel physicogenomic study. Nephrol Dial Transplant. 2013 May;28(5):1284–93. Epub 2013 Jan 22. pmid:23345623.
- 16. Bashar K, Healy D, Browne LD, Kheirelseid EA, Walsh MT, Clarke-Moloney M, et al. Role of far infra-red therapy in dialysis arterio-venous fistula maturation and survival: systematic review and meta-analysis. PLoS One. 2014 Aug 12;9(8):e104931. pmid:25115802; PMCID: PMC4130633.
- 17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021 Jun;134:178–189. Epub 2021 Mar 29. pmid:33789819.
- 18. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from: www.training.cochrane.org/handbook.
- 19. The Nordic Cochrane Centre TCc (2012) Review Manager (RevMan) [Computer Program]. Version 5.2.
- 20. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol. 2007 Mar;18(3):985–92. Epub 2007 Jan 31. pmid:17267744.
- 21. Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013 Aug;62(2):304–11. Epub 2013 Mar 6. pmid:23474008.
- 22. Anand SM, Fernando ME, Suhasini B, Valarmathi K, Elancheralathan K, Srinivasaprasad ND, et al. The Role of Far Infrared Therapy in the Unassisted Maturation of Arterio-venous Fistula in Patients with Chronic Kidney Disease. Indian J Nephrol. 2020 Sep-Oct;30(5):307–315. Epub 2020 Aug 27. pmid:33707817; PMCID: PMC7869642.
- 23. Lai CC, Fang HC, Mar GY, Liou JC, Tseng CJ, Liu CP. Post-angioplasty far infrared radiation therapy improves 1-year angioplasty-free hemodialysis access patency of recurrent obstructive lesions. Eur J Vasc Endovasc Surg. 2013 Dec;46(6):726–32. Epub 2013 Sep 25. pmid:24119468.
- 24. Brooke BS, Griffin CL, Kraiss LW, Kim J, Nelson R. Cost-effectiveness of repeated interventions on failing arteriovenous fistulas. J Vasc Surg. 2019 Nov;70(5):1620–1628. Epub 2019 May 27. pmid:31147114.
- 25. Kipshidze N, Nikolaychik V, Muckerheidi M, Keelan MH, Chekanov V, Maternowski M, et al. Effect of short pulsed nonablative infrared laser irradiation on vascular cells in vitro and neointimal hyperplasia in a rabbit balloon injury model. Circulation. 2001 Oct 9;104(15):1850–5. pmid:11591625.
- 26. Ohori T, Nozawa T, Ihori H, Shida T, Sobajima M, Matsuki A, et al. Effect of repeated sauna treatment on exercise tolerance and endothelial function in patients with chronic heart failure. Am J Cardiol. 2012 Jan 1;109(1):100–4. Epub 2011 Sep 23. pmid:21944673.